EWTX NASDAQ
Edgewise Therapeutics, Inc.
1W: +5.8%
1M: +1.9%
3M: +30.9%
YTD: +87.0%
1Y: +202.7%
3Y: +584.1%
5Y: +169.2%
$44.40
+1.50 (+3.50%)
Weekly Expected Move ±5.8%
$39
$42
$44
$47
$50
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$4.8B
52W Range13.685-48.4
Volume1,306,570
Avg Volume1,371,220
Beta0.28
Dividend—
Analyst Ratings
Company Info
CEOKevin Koch
Employees127
SectorHealthcare
IndustryBiotechnology
IPO Date2021-03-26
Websiteedgewisetx.com
1715 38th Street
Boulder, CO 80301
US
Boulder, CO 80301
US
303 735 8373
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Latest News
91,638 Shares in Edgewise Therapeutics, Inc. $EWTX Acquired by Hsbc Holdings PLC
12,365 Shares in Edgewise Therapeutics, Inc. $EWTX Purchased by Corient Private Wealth LP
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?
Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?
Can Camzyos' Growth Offset Bristol Myers' Patent Pressures?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Donovan Joanne M. | S-Sale | 2,919 | $43.41 | 2026-08-13 |
| Nofi Michael | A-Award | 48,750 | $43.56 | 2026-08-12 |
| Donovan Joanne M. | A-Award | 65,000 | $43.56 | 2026-08-12 |
| Russell Alan J | A-Award | 65,000 | $43.56 | 2026-08-12 |
| MOORE JOHN R | A-Award | 65,000 | $43.56 | 2026-08-12 |